-
Je něco špatně v tomto záznamu ?
Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?
A. Grohová, K. Dáňová, R. Špíšek, L. Palová-Jelínková,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
PubMed
30804929
DOI
10.3389/fimmu.2019.00079
Knihovny.cz E-zdroje
- MeSH
- dendritické buňky imunologie metabolismus transplantace MeSH
- diabetes mellitus 1. typu imunologie MeSH
- hyperglykemie imunologie MeSH
- imunologická tolerance účinky léků MeSH
- imunoterapie adoptivní metody MeSH
- klinické zkoušky jako téma MeSH
- lidé MeSH
- mezenchymální kmenové buňky imunologie MeSH
- mitochondrie metabolismus MeSH
- monitorování fyziologických funkcí MeSH
- přeprogramování buněk MeSH
- reaktivní formy kyslíku metabolismus MeSH
- regulační T-lymfocyty imunologie transplantace MeSH
- transplantace mezenchymálních kmenových buněk MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Diabetes mellitus is characterized by long standing hyperglycemia leading to numerous life-threatening complications. For type 1 diabetes mellitus, resulting from selective destruction of insulin producing cells by exaggerated immune reaction, the only effective therapy remains exogenous insulin administration. Despite accurate compliance to treatment of certain patients, transient episodes of hyperglycemia cannot be completely eliminated by this symptomatic treatment. Novel immunotherapeutic approaches based on tolerogenic dendritic cells, T regulatory cells and mesenchymal stem cells (MSCs) have been tested in clinical trials, endeavoring to directly modulate the autoimmune destruction process in pancreas. However, hyperglycemia itself affects the immune system and the final efficacy of cell-based immunotherapies could be affected by the different glycemic control of enrolled patients. The present review explores the impact of hyperglycemia on immune cells while providing greater insight into the molecular mechanisms of high glucose action and subsequent metabolic reprogramming of different immune cells. Furthermore, over-production of mitochondrial reactive oxygen species, formation of advanced glycation end products as a consequence of hyperglycemia and their downstream signalization in immune cells are also discussed. Since hyperglycemia in patients with type 1 diabetes mellitus might have an impact on immune-interventional treatment, the maintenance of a tight glucose control seems to be beneficial in patients considered for cell-based therapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006565
- 003
- CZ-PrNML
- 005
- 20200526100534.0
- 007
- ta
- 008
- 200511s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fimmu.2019.00079 $2 doi
- 035 __
- $a (PubMed)30804929
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Grohová, Anna $u SOTIO a.s., Prague, Czechia. Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University in Prague, Prague, Czechia. Department of Pediatrics, Charles University in Prague, Second Faculty of Medicine, University Hospital Motol, Prague, Czechia.
- 245 10
- $a Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account? / $c A. Grohová, K. Dáňová, R. Špíšek, L. Palová-Jelínková,
- 520 9_
- $a Diabetes mellitus is characterized by long standing hyperglycemia leading to numerous life-threatening complications. For type 1 diabetes mellitus, resulting from selective destruction of insulin producing cells by exaggerated immune reaction, the only effective therapy remains exogenous insulin administration. Despite accurate compliance to treatment of certain patients, transient episodes of hyperglycemia cannot be completely eliminated by this symptomatic treatment. Novel immunotherapeutic approaches based on tolerogenic dendritic cells, T regulatory cells and mesenchymal stem cells (MSCs) have been tested in clinical trials, endeavoring to directly modulate the autoimmune destruction process in pancreas. However, hyperglycemia itself affects the immune system and the final efficacy of cell-based immunotherapies could be affected by the different glycemic control of enrolled patients. The present review explores the impact of hyperglycemia on immune cells while providing greater insight into the molecular mechanisms of high glucose action and subsequent metabolic reprogramming of different immune cells. Furthermore, over-production of mitochondrial reactive oxygen species, formation of advanced glycation end products as a consequence of hyperglycemia and their downstream signalization in immune cells are also discussed. Since hyperglycemia in patients with type 1 diabetes mellitus might have an impact on immune-interventional treatment, the maintenance of a tight glucose control seems to be beneficial in patients considered for cell-based therapy.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a přeprogramování buněk $7 D065150
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a dendritické buňky $x imunologie $x metabolismus $x transplantace $7 D003713
- 650 _2
- $a diabetes mellitus 1. typu $x imunologie $7 D003922
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperglykemie $x imunologie $7 D006943
- 650 _2
- $a imunologická tolerance $x účinky léků $7 D007108
- 650 _2
- $a imunoterapie adoptivní $x metody $7 D016219
- 650 _2
- $a transplantace mezenchymálních kmenových buněk $7 D045164
- 650 _2
- $a mezenchymální kmenové buňky $x imunologie $7 D059630
- 650 _2
- $a mitochondrie $x metabolismus $7 D008928
- 650 _2
- $a monitorování fyziologických funkcí $7 D008991
- 650 _2
- $a reaktivní formy kyslíku $x metabolismus $7 D017382
- 650 _2
- $a regulační T-lymfocyty $x imunologie $x transplantace $7 D050378
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Dáňová, Klára $u SOTIO a.s., Prague, Czechia. Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University in Prague, Prague, Czechia.
- 700 1_
- $a Špíšek, Radek $u SOTIO a.s., Prague, Czechia. Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University in Prague, Prague, Czechia.
- 700 1_
- $a Palová-Jelínková, Lenka $u SOTIO a.s., Prague, Czechia. Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University in Prague, Prague, Czechia.
- 773 0_
- $w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 10, č. - (2019), s. 79
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30804929 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200526100530 $b ABA008
- 999 __
- $a ok $b bmc $g 1525423 $s 1096621
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 10 $c - $d 79 $e 20190205 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
- LZP __
- $a Pubmed-20200511